Last updated 7 days ago
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
1000 patients around the world
Available in Spain, Brazil, Argentina, United States
Alexion Pharmaceuticals, Inc.
1000Patients around the world
This study is for people with
Rare diseases
Amyloidosis
Requirements for the patient
To 90 Years
All Gender
Medical requirements
- Centrally confirmed diagnosis of ATTR-CM with either wild-type or variant TTR genotypeEnd-diastolic interventricular septal wall thickness ≥ 11 mm for women or ≥ 12 mm for men on echocardiography measured at ScreeningNT-proBNP > 2000 pg/mL at ScreeningTreatment with a loop diuretic for at least 30 days prior to ScreeningHistory of heart failure NYHA Class II-IV at ScreeningLife expectancy of ≥ 6 months as per the Investigator's judgmentMales and females of childbearing ability must use contraception
- Known leptomeningeal amyloidosisKnown light chain (AL) or secondary amyloidosis (AA), or any other form of systemic amyloidosisAcute coronary syndrome, unstable angina, stroke, transient ischemic attack, coronary revascularization, cardiac device implantation, cardiac valve repair, or major surgery within 3 months of ScreeningUncontrolled clinically significant cardiac arrhythmia, per Investigator's assessmentLVEF < 30% on echocardiographyRenal failure requiring dialysis or an eGFR < 20 mL/min/1.73 m2 at ScreeningPolyneuropathy with PND score IV
StudyDepleTTR-CM
SponsorAlexion Pharmaceuticals, Inc.
Conditions
Amyloidosis
Requirements
To 90 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06183931
